Related Experiment Video
Updated: May 15, 2025
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
161
Consensus to Reduce Withdrawal and Improve Adherence with SGLT2i: Consensus TWO SGLT2i Adherence Group
Nagendra K Singh1, Akash Kumar Singh2, Bijay Patni3
1Director, Department of Medicine, Diabetes and Heart Centre, Dhanbad, Jharkhand, India, Orcid: https://orcid.org/0000-0001-9485-1663, Corresponding Author.
The Journal of the Association of Physicians of India
|April 9, 2025
Summary
Understanding nonadherence to sodium-glucose co-transporter-2 inhibitors (SGLT2i) is key for better diabetes management. Addressing patient factors and improving communication can enhance SGLT2i treatment adherence.
Area of Science:
- Endocrinology
- Pharmacology
- Cardiology
Background:
- Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are effective for blood glucose control and offer cardiorenal protection.
- Nonadherence and discontinuation of SGLT2i treatment present challenges in patient care.
Purpose of the Study:
- To analyze factors contributing to nonadherence and discontinuation of SGLT2i therapy.
- To identify strategies for enhancing patient compliance and reducing withdrawal rates.
Main Methods:
- A consensus was reached by an expert committee of 14 leaders in type 2 diabetes mellitus (T2D) and SGLT2i therapy.
- An extensive literature review informed discussions on adherence challenges and best practices.
- Virtual meetings facilitated in-depth discussions to formulate actionable recommendations.
Main Results:
- Factors influencing nonadherence include race (Black), older age, lower socioeconomic status, longer diabetes duration, comorbidities, genital infections, and limited healthcare access.
- Appropriate patient selection and comprehensive education on indications, interactions, and side effects are vital for adherence.
Conclusions:
- Regular monitoring, lifestyle modifications, and open patient-practitioner communication are essential for maintaining adherence.
- Personalized care plans, patient education, prompt concern resolution, and collaborative relationships are critical for sustained SGLT2i treatment.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
139
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
139
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
126
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
126
01:24Glucagon-like Receptor Agonists
272
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272
01:06Oral Hypoglycemic Agents: Glinides
112
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
112
01:17Oral Hypoglycemic Agents: Sulfonylureas
165
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
165